skip navigation links
National Cancer Institute
Enterprise Vocabulary Services
Box
NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)
SearchBox Top
SearchBox Bottom
Methotrexate (CUI C0025677) Suggest changes to this concept
Add to Cart

Terms & Properties

Concept Unique Identifier (CUI): C0025677

NCI Thesaurus Code: C642  (see NCI Thesaurus info)

Semantic Type: Amino Acid, Peptide, or Protein

Semantic Type: Pharmacologic Substance

NCIt Definition: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

PDQ Definition: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear. Check for active clinical trials using this agent. (NCI Thesaurus)

NCI-GLOSS Definition: A drug used to treat some types of cancer, rheumatoid arthritis, and severe skin conditions, such as psoriasis. Amethopterin stops cells from making DNA and may kill cancer cells. It is a type of antimetabolite.

CSP Definition: folic acid antagonist that acts by inhibiting the synthesis of nucleic acids, thymidylate, and protein; used as an antineoplastic in a wide variety of malignancies, and as an antipsoriatic and antirheumatic.

MSH Definition: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

NPO Definition: A pteridine compound has a pteridine substructure; which has functional parent, L-glutamic acid; which has other substructures that classify it a monocarboxylic acid amide and a dicarboxylic acid.

Synonyms & Abbreviations: (see Synonym Details)
4-amino-10-methylfolic acid
4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid
4-amino-N(10)-Methylpteroylglutamic acid
4291
59-05-2
740
7723
Abitrexate
Alpha-Methopterin
amethopterin
Brimexate
CL 14377
CL-14377
Emtexate
Emthexate
Emthexat
Farmitrexat
Fauldexato
Folex PFS
Folex
L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-
Lantarel
Ledertrexate
Lumexon
Maxtrex
Medsatrexate
Metex
Methoblastin
Methotrexate (substance)
Methotrexate [Chemical/Ingredient]
Methotrexate LPF
Methotrexate Methylaminopterin
methotrexate
Methotrexatum
Methotrexat
methylaminopterin
Metotrexato
Metrotex
Mexate-AQ
Mexate
MTX - Methotrexate
MTX
Méthotrexate
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Novatrex
Product containing methotrexate (medicinal product)
Product containing methotrexate
Rheumatrex
Texate
Tremetex
Trexall
Trexeron
Trixilem
WR-19039

External Source Codes: 
NCI Thesaurus Code C642 (see NCI Thesaurus info)
CAS Registry Number 59-05-2 (see NLM ChemIDplus info)
FDA UNII Code YL5FZ2Y5U1
NSC Code 740 (see NCI DTP info)
PDQ Closed Trial Search ID 41719
PDQ Open Trial Search ID 41719 (check for NCI PDQ open clinical trial info)

Other Properties: Property Definitions
Name Value Source
Accepted_Therapeutic_Use_For Abortion; Bladder cancer; Breast cancer; Carcinomatous; meningitis; Chorioadenoma destruens; Crohn's disease; Ectopic pregnancy; Esophageal cancer; Gestational choriocarcinoma NCI
Accepted_Therapeutic_Use_For Graft versus host disease-prophylaxis; Head/neck cancer; Hydatidiform mole; Leukemia; meningeal; Lymphomas; Acute Lymphoblastic Leukemia; Burkitt's; Lung cancer; Mycosis fungoides; Osteosarcoma; Psoriasis; Rheumatoid arthritis; Wegener's granulomatosis NCI
ACTIVE 1 SNOMEDCT_US
ANSWER_CODE 8 LNC
AQL AA AD AE AG AI AN BL CF CH CL CS CT EC HI IM IP ME PD PK PO RE SD ST TO TU UR MSH
CASE_SIGNIFICANCE_ID 900000000000017005 SNOMEDCT_US
CASE_SIGNIFICANCE_ID 900000000000448009 SNOMEDCT_US
CHARACTERISTIC_TYPE_ID 900000000000011006 SNOMEDCT_US
CHEBI_ID CHEBI:44185 NCI
Chemical_Formula C20H22N8O5 NCI
CODE NPO_741 NPO
Contributing_Source CTRP NCI
Contributing_Source FDA NCI
CTV3ID h34.. SNOMEDCT_US
CTV3ID XUWvR SNOMEDCT_US
DATE_LAST_MODIFIED 2015-12-03 PDQ
DB_XR_ID CHEBI:44185 NPO
DB_XR_ID NCIT:C642 NPO
DC 1 MSH
DEFINITION_STATUS_ID 900000000000074008 SNOMEDCT_US
DID 1175-1202 CSP
DX 19660101 MSH
EFFECTIVE_TIME 20020131 SNOMEDCT_US
EFFECTIVE_TIME 20030131 SNOMEDCT_US
EXTERNALLY_DEFINED N LNC
FDA_UNII_CODE YL5FZ2Y5U1 DRUGBANK
FDA_UNII_CODE YL5FZ2Y5U1 NDFRT
LEVEL Example Part D Eligible Drugs USPMG
LEVEL Ingredient NDFRT
LT TRD MSH
LT TRD MTH
LT TRD PDQ
MDA 19990101 MSH
MESH_DEFINITION An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. NDFRT
MESH_DUI D008727 NDFRT
MESH_NAME Methotrexate NDFRT
MESH_UI M0013595 NDFRT
MMR 20160531 MSH
MN D03.633.100.733.631.192.500 MSH
MODIFIER_ID 900000000000451002 SNOMEDCT_US
NCI_THESAURUS_CODE C642 PDQ
NDFRT_KIND DRUG_KIND NDFRT
NDFRT_KIND INGREDIENT_KIND NDFRT
NUI N0000007370 NDFRT
NUI N0000147916 NDFRT
ORIG_STY Drug/agent PDQ
PA D000020 MSH
PA D000964 MSH
PA D003879 MSH
PA D004791 MSH
PA D005493 MSH
PA D007166 MSH
PA D018501 MSH
PA D019384 MSH
PID 489 PDQ
RDF_ID CHEBI_44185 NPO
RN 0 MSH
RN YL5FZ2Y5U1 MSH
RR 133073-73-1 (x.H2O) MSH
RR 15475-56-6 (Na salt) MSH
RR 3IG1E710ZN MSH
RR 51865-79-3 ((D)-isomer) MSH
RR 59-05-2 (Methotrexate) MSH
RR 60388-53-6 ((DL)-isomer) MSH
RR 86669-44-5 (di-Cs salt) MSH
RXAUI 1001202 RXNORM
RXAUI 1533417 RXNORM
RXAUI 2072304 RXNORM
RXAUI 222736 RXNORM
RXAUI 2305465 RXNORM
RXAUI 2851413 RXNORM
RXAUI 3108077 RXNORM
RXAUI 3185228 RXNORM
RXAUI 3193289 RXNORM
RXAUI 3193290 RXNORM
RXAUI 3198320 RXNORM
RXAUI 3198321 RXNORM
RXAUI 6395663 RXNORM
RXAUI 6396336 RXNORM
RXCUI 152008 RXNORM
RXCUI 346424 RXNORM
RXCUI 491604 RXNORM
RXCUI 6851 RXNORM
RXN_ACTIVATED 01/28/2010 RXNORM
RXN_BN_CARDINALITY single RXNORM
RXN_OBSOLETED 03/27/2013 RXNORM
RXN_OBSOLETED 08/30/2007 RXNORM
SID APRD00353 DRUGBANK
SOS An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear. NPO
SPL_SET_ID 03c66d8c-186a-4923-9a32-07ab07d472ad MTHSPL
SPL_SET_ID 0d63ba29-b692-41b4-87e8-351265c8273f MTHSPL
SPL_SET_ID 0e30eaef-5a09-4104-8a11-c32933eadeab MTHSPL
SPL_SET_ID 173afe3e-a619-41e0-a8e8-2c27e4c300da MTHSPL
SPL_SET_ID 18705002-da4b-4562-b0d9-df3d56a16c84 MTHSPL
SPL_SET_ID 223fde57-7b13-4fd7-90e2-f74fc0846431 MTHSPL
SPL_SET_ID 2308cd6e-b712-438f-8de2-7a64b89aefb8 MTHSPL
SPL_SET_ID 271ff7a2-4904-a0ae-778e-0b5ec8e78d76 MTHSPL
SPL_SET_ID 27dd39ca-207e-44db-8da1-a0689f0d6b6f MTHSPL
SPL_SET_ID 2cb70aa1-f73a-41c8-9a7f-edbcf1a06efd MTHSPL
SPL_SET_ID 346ec9ce-dc98-4a55-b55e-d3af11f2d703 MTHSPL
SPL_SET_ID 3614d085-c313-4ce8-8a70-888899b6406e MTHSPL
SPL_SET_ID 405d2b6c-b465-41de-ad93-1e009825cd3b MTHSPL
SPL_SET_ID 4767fe9f-aa42-46cd-8101-9df7101f55e1 MTHSPL
SPL_SET_ID 478a4c35-4b99-4eb2-badd-68ea144812c1 MTHSPL
SPL_SET_ID 47bb478d-0e3e-423a-9737-1231152add1d MTHSPL
SPL_SET_ID 4a246ce7-c04e-4119-9201-23e5f90152a8 MTHSPL
SPL_SET_ID 57b2face-9edd-4aea-bbc4-938249aa2267 MTHSPL
SPL_SET_ID 5c960719-19a3-442d-a24b-189b4760ab69 MTHSPL
SPL_SET_ID 68623ad0-a395-4847-88d4-48413c1f4fcf MTHSPL
SPL_SET_ID 6cf2e15a-6286-41f7-aa7d-3968d735c864 MTHSPL
SPL_SET_ID 70c09984-2b36-424f-8b27-3fd0cd4e833d MTHSPL
SPL_SET_ID 757d6cef-6696-7a1c-8074-01258aaa8bdd MTHSPL
SPL_SET_ID 78794e3d-f293-4eeb-22ac-8f536d5947eb MTHSPL
SPL_SET_ID 7a64db41-d38e-4228-9f9a-40a9e306ef83 MTHSPL
SPL_SET_ID 7b918398-c33e-44cd-8133-eeb85d36ab9e MTHSPL
SPL_SET_ID 8df0780e-0fbd-4ab8-80b0-7a5eaa08ec0a MTHSPL
SPL_SET_ID 9ab8ce16-f7de-41d4-a4c8-1c742621b6d5 MTHSPL
SPL_SET_ID 9b34b1d8-d125-41a2-9f6f-3fab67b573bd MTHSPL
SPL_SET_ID 9c4a4784-b063-4c8f-b915-aeb18cb149be MTHSPL
SPL_SET_ID ab0e9947-9f7c-47cb-9c1d-964f5009681d MTHSPL
SPL_SET_ID ac6b294d-ac19-4bea-9d8b-bd1bc6d13afe MTHSPL
SPL_SET_ID ade151b9-b433-47dc-90f5-f6463f70c2fd MTHSPL
SPL_SET_ID b42be739-2999-496c-bb2e-e2971735173a MTHSPL
SPL_SET_ID b585f621-f6c9-4735-ab61-bd1b401f3df0 MTHSPL
SPL_SET_ID b78cd35a-31ae-4404-9b15-eaffaaba42a0 MTHSPL
SPL_SET_ID cc8dcff0-1476-414b-a4f7-39c322b6ff84 MTHSPL
SPL_SET_ID d0075461-0e7e-4967-9c9b-d6440e912c0e MTHSPL
SPL_SET_ID d71b1856-99d8-4a9e-9189-f87b6675f80a MTHSPL
SPL_SET_ID d85e0fbd-89ff-4157-abe6-87ce307658be MTHSPL
SPL_SET_ID dd035a9f-cd40-4314-b9d8-2294b8a924e2 MTHSPL
SPL_SET_ID e35ffbb9-e339-4e00-b395-7e4d3a2aeb01 MTHSPL
SPL_SET_ID e7363e0a-049b-4bf1-8317-606b134f32f7 MTHSPL
SPL_SET_ID e942f8db-510f-44d6-acb5-b822196f5e8c MTHSPL
SPL_SET_ID ec476b11-0b3c-4139-b1eb-a3daa76bc271 MTHSPL
SPL_SET_ID f13eeab7-f376-4912-aef2-450ea027de6d MTHSPL
SPL_SET_ID fd0f56ef-d598-4735-9bc5-beca06ea814d MTHSPL
SUBSET_MEMBER 900000000000497000~MAPTARGET~h34.. SNOMEDCT_US
SUBSET_MEMBER 900000000000497000~MAPTARGET~XUWvR SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
TERMUI T025976 MSH
TERMUI T025977 MSH
TERMUI T025978 MSH
TERMUI T094530 MSH
TH BAN (19XX) MSH
TH FDA SRS (2014) MSH
TH INN (19XX) MSH
TH NLM (1978) MSH
TH NLM (2014) MSH
TH UNK (19XX) MSH
TH USAN (1961) MSH
TH USP (19XX) MSH
TYPE_ID 900000000000003001 SNOMEDCT_US
TYPE_ID 900000000000013009 SNOMEDCT_US
UI1_HAS_ROLE payload agent role~NPO_635 NPO
VANDF_RECORD 50.416^2451^Active/Master NDFRT
VANDF_RECORD 50.6^254^Active/Master NDFRT
VUID 4019828 NDFRT

Additional Concept Data:  (none)

URL to Bookmark: https://ncim-stage.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=C0025677

Mainbox Bottom